|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500097750 |
|
最近更新日期: Date of Last Refreshed on: |
2025-02-25 11:49:04 |
|
注册时间: Date of Registration: |
2025-02-25 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
批注:1.请确认该研究征募起始时间及状态填写是否合理准确(纳排标准和采集人体标本下方,此项重要):已开始研究,首例参试者知情时间=征募开始时间,末例知情时间=征募结束时间;请补充首例(如研究已结束需提供末例)参试者签署的知情同意书(隐去个人隐私信息)后与知情同意书模板合并上传;并将征募时间调整一致;未开始研究,请将征募时间往后延,针对补注册要求有共享原始数据计划,请完善“共享原始数据的方式”一栏,填写预计共享的时间、方式(具备公示功能的平台)即可。在最终共享提交数据时,请与贵单位报备,经过审核后方可共享;2.请确认该研究是否已完成备案,若没有备案,请至医学研究登记备案信息系统备案(https://www.medicalresearch.org.cn/login),(是否在中国临床试验注册中心公开选择“否”),备案完成后请将带有备案号界面的完整截图与伦理批件合并为一个文件上传。如已备案,请备注已备案,谢谢!为避免重复提交,耽误审核进度,请全部修好后再提交。请预留修改时间。睡眠障碍的机制探究及神经调控技术的治疗前景 |
|
Public title: |
Exploring the mechanism of sleep disorders and the therapeutic prospect of neuroregulation techniques |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
睡眠障碍的机制探究及神经调控技术的治疗前景 |
|
Scientific title: |
Exploring the mechanism of sleep disorders and the therapeutic prospect of neuroregulation techniques |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李矜玥 |
研究负责人: |
李矜玥 |
|
Applicant: |
Jinyue Li |
Study leader: |
Jinyue Li |
|
申请注册联系人电话: Applicant telephone: |
+86 159 6080 3380 |
研究负责人电话:
Study leader's |
+86 159 6080 3380 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
641605931@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
li.jinyue@zsxmhospital.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
福建省厦门市湖里区金湖路668号 |
研究负责人通讯地址: |
福建省厦门市湖里区金湖路668号 |
|
Applicant address: |
No. 668, Jinhu Road, Huli District, Xiamen City, Fujian Province |
Study leader's address: |
No. 668, Jinhu Road, Huli District, Xiamen City, Fujian Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
复旦大学附属中山医院厦门医院 |
||
|
Applicant's institution: |
Zhongshan Hospital and Xiamen Hospital affiliated to Fudan University |
||
|
研究负责人所在单位: |
复旦大学附属中山医院厦门医院 |
||
|
Affiliation of the Leader: |
Zhongshan Hospital and Xiamen Hospital affiliated to Fudan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
B2024-059R |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
复旦大学附属中山医院厦门医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Zhongshan Hospital, Xiamen Hospital, Fudan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-08-12 00:00:00 | ||
|
伦理委员会联系人: |
张博恒 |
||
|
Contact Name of the ethic committee: |
Boheng Zhang |
||
|
伦理委员会联系地址: |
福建省厦门市湖里区金湖路668号 |
||
|
Contact Address of the ethic committee: |
No. 668, Jinhu Road, Huli District, Xiamen City, Fujian Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 592 356 9860 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
复旦大学附属中山医院厦门医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Zhongshan Hospital and Xiamen Hospital affiliated to Fudan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
福建省厦门市湖里区金湖路668号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 668, Jinhu Road, Huli District, Xiamen City, Fujian Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
厦门市科技计划项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Science direction Project |
||||||||||||||||||||||
|
研究疾病: |
睡眠障碍 |
||||||||||||||||||||||
|
Target disease: |
Sleep disorder |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究探讨功能性神经调控技术是否可通过抑制或激活不同的脑区、调控觉醒-睡眠环路、进而改善失眠患者的临床症状。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study investigated whether functional neuroregulatory techniques can improve the clinical symptoms of insomnia patients by inhibiting or activating different brain regions and regulating the wakeful-sleep circuit. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
慢性失眠患者入选标准 1.年龄18-79岁。 2.符合美国《精神病学协会精神障碍诊断与统计手册》第五版(DSM-V)中慢性失眠的诊断标准,基线PSQI评分>6分。 3.无其他的睡眠障碍(如睡眠相关运动障碍、过度睡眠或睡眠异常); 4.治疗前4周内服用药物无变化; 5.自愿签署书面知情同意书。 健康对照组入选标准 1.年龄18-79岁; 2.否认睡眠障碍的病史(PSQI评分<=5分); 3.否认神经或精神障碍病史,如抑郁状态或焦虑状态等。 |
||||||||||||||||||||||
|
Inclusion criteria |
Inclusion criteria for patients with chronic insomnia 1. Age 18-79 years old. 2. Meet the diagnostic criteria for chronic insomnia in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), with a baseline PSQI score of > 6. 3. No other sleep disorders (such as sleep-related movement disorders, excessive sleepiness or sleep abnormalities); 4. No change in medication taken within 4 weeks before treatment; 5. Voluntarily signed written informed consent. Inclusion criteria for the healthy control group 1. Age 18-79 years old; 2. Denial of a history of sleep disturbance (PSQI score < = 5 points); 3. Denial of a history of neurological or psychiatric disorders, such as depressive states or anxious states, etc. |
||||||||||||||||||||||
|
排除标准: |
1.有癫痫病史或严重头部外伤,存在植入医疗器械(如起搏器、耳内助听器佩戴等)者,或妊娠状态。 2.严重的神经或精神疾病或医疗状况(如颅骨缺损和开颅手术)或其他可能影响睡眠的疾病。 3.有严重的肝、肾、心脑血管、造血系统疾病及其他严重并发症。 4.大量酗酒、滥用药物(含安眠药)。 5.无法配合完成治疗,无法完成核磁共振和神经心理学评估。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Those with a history of epilepsy or severe head trauma, implanted medical devices (such as pacemakers, in-ear hearing aids, etc.), or pregnancy. 2. Severe neurological or psychiatric illness or medical condition (such as skull defect and craniotomy) or other conditions that may affect sleep. 3. Serious liver, kidney, cardiovascular and cerebrovascular, hematopoietic system diseases and other serious complications. 4. Heavy alcohol abuse and drug abuse (including sleeping pills). 5. Unable to cooperate with the completion of treatment, unable to complete MRI and neuropsychological evaluation. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-02-25 00:00:00至 To 2026-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-02-25 00:00:00 至 To 2026-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机数生成器 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Random number generator |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
双盲,对研究参与者和研究者设盲 |
|
Blinding: |
Double-blind, blinding the study participants and investigators |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |